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Background
Data collected for a clinical trial should have errors at the
minimum level; high rates of data discrepancy or incom-
pleteness may affect validity of the trial conclusions. Proof
of data quality is also an essential requirement for regula-
tory bodies. The study objectives were to present best prac-
tices and assess data management process and data
quality of the largest trial.
Methods
Data were extracted from phase III vaccine trial conducted
among Thai adults. This study began in 2003 and closed
out in July 2009. To meet scientific and ethical standards,
good clinical data management practice (GCDMP) had
been implemented to obtain high quality data.
Results
The CDM process was prepared at the trial initiation. The
systems were routinely validated; the data, IT and quality
assurance staff were trained to complete their responsibil-
ities effectively. The data collected in this study met CDM
metrics in both quantity and quality. In this study, 16,402
healthy volunteers enrolled into the study for 3 years fol-
low-up. Of the 1,148,839 case record forms (CRFs), there
were 82,502 QCs composed of 21% missing data and
22% inconsistent values; time to QC resolved ranged
from 7 to 11 days. There were 2,691 events of protocol
deviation captured and all get resolved timely. Data cod-
ing was done for 27,714 AEs and 2,925 SAEs using Med-
DRA; the AE and SAE databases were reconciled prior to
the study closure. Source document and CRFs were 100%
verified; the accuracy assessment for efficacy and safety
data was performed before declaration of clean databases
for final analysis.
Conclusion
The trial had been conducted under GCDMP; best prac-
tices in quality assurance and quality control was crucial
in making this trial analysis datasets valid and reliable.
The results of this study were scientifically sound and in
compliance with the protocol and all aspects of trial con-
duct.
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